期刊
CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY
卷 16, 期 -, 页码 27-38出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/CCID.S378135
关键词
plaque psoriasis; PASI; patient-reported outcomes; Dermatology Quality of Life Index; Hospital Anxiety and Depression Scale
类别
This study analyzed the gender-related differences in the efficacy of secukinumab 300 mg and its impact on quality of life in patients with moderate to severe psoriasis. The results showed that secukinumab was effective in treating psoriasis and improving quality of life, regardless of gender.
Purpose: Psoriasis, a common systemic inflammatory disorder, presents with gender-related differences in the quality of life (QoL) and treatment outcomes. This post hoc analysis from the Phase 3b SUPREME study explored gender-related differences in patient characteristics and efficacy of secukinumab 300 mg on Psoriasis Area and Severity Index (PASI) 75/90/100 and impact on QoL using the Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis through week 24.Patients and Methods: The proportion of patients achieving PASI 75/90/100 was computed using a nonresponder imputation approach. Differences between cohorts were analyzed using a logistic regression model. The mean change from baseline in DLQI was computed using the Wilcoxon test.Results: Among the 433 patients (males: 71.6%), females had a higher DLQI than males at baseline (13.1 vs 9.5; P<0.0001). Males had a slightly higher response for PASI 90 than females at week 16 (80.7% vs 78.1%; P=0.0779) and 24 (83.2% vs 79.7%; P=0.0319). No differences were observed between genders in PASI 100/75 responses at week 24. Both genders showed an improvement in DLQI with secukinumab at week 24 (-10.9 vs -8.1, respectively, in females vs males; P=0.0004).Conclusion: In summary, secukinumab was effective in the treatment of psoriasis, irrespective of gender.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据